An intracerebral hemorrhage (ICH) is a hemorrhagic stroke that is caused by bleeding from a blood vessel in the brain. Intracerebral hemorrhages have a high risk of death and disability and expansion of the hemorrhage is predictive of a poorer outcome. The purpose of this study is to find out if there is a benefit to reducing systolic blood pressure (SBP) in a more intensive way (keeping SBP less than 140 mmHg) compared with standard SBP treatment (keeping SBP less than 180 mmHg). This study uses an FDA approved drug called nicardipine to reduce the blood pressure after ICH. Reducing blood pressure in the early stages of ICH is thought to limit the amount of brain damage that occurs. Less brain damage may reduce the high levels of death and disability commonly found in this form of stroke. The primary way the study team will measure if intensive SBP treatment is better than standard SBP treatment is by following the patient’s stroke recovery for 90 days.
For more information: https://clinicaltrials.gov/ct2/show/NCT01176565?term=ATACH+II&rank=1